Ribociclib, another CDK4/CDK6 kinase inhibitor, enhanced glucocorticoid sensitivity in primary cultures derived from bone marrow of pediatric B-precursor ALL patients (96). Here, CDK6 is linked to acute lymphoblastic leukemia.